Hansoh Pharma announced that its self-developed antibody-drug conjugate HS-20093 achieved the primary endpoint of overall survival in the pivotal Phase III ARTEMIS-008 study for patients with advanced or relapsed small cell lung cancer following platinum-based therapy.
At the pre-specified interim analysis, HS-20093 showed a statistically significant and clinically meaningful survival advantage over the comparator therapy, topotecan. Consistent efficacy improvements were also observed across secondary measures, including progression-free survival.
The safety profile remained in line with earlier clinical findings, and no new safety signals were detected.
Following the positive read-out, Hansoh Pharma plans to begin discussions with Chinese regulators to prepare a biologics license application. Full study details are slated for presentation at an upcoming international oncology conference.
The announcement was issued by the board of directors on 10 July 2026.
